• Molecular NamePromazine
  • SynonymChlorpromazine Hcl; CPZ; Phenothiazine; Promazin; Promazina; Promazine Hcl
  • Weight284.427
  • Drugbank_IDDB00420
  • ACS_NO58-40-2
  • Show 3D model
  • LogP (experiment)4.55
  • LogP (predicted, AB/LogP v2.0)4.6
  • pka9.4
  • LogD (pH=7, predicted)2.45
  • Solubility (experiment)0.0143 mg/ml
  • LogS (predicted, ACD/Labs)(ph=7)-2.39
  • LogSw (predicted, AB/LogsW2.0)0.01
  • Sw (mg/ml) (predicted, ACD/Labs)0.01
  • No.of HBond Donors0
  • No.of HBond Acceptors2
  • No.of Rotatable Bonds4
  • TPSA31.78
  • StatusFDA approved; US withdrawn
  • AdministrationN/A
  • PharmacologyA medication that belongs to the phenothiazine class of antipsychotics. An older medication used to treat schizophrenia, it is still prescribed, alongside newer agents such as olanzapine and quetiapine.
  • Absorption_valueN/A
  • Absorption (description)Absorption may be erratic and peak plasma concentrations show large interindividual differences.
  • Caco_2N/A
  • Bioavailability16.25
  • Protein binding90.0
  • Volume of distribution (VD)7.5 L/kg
  • Blood/Plasma Partitioning ratio (D_blood)N/A
  • MetabollsmHepatic, primarily to N-desmethylpromazine and promazine sulfoxide.
  • Half lifeN/A
  • ExcretionN/A
  • Urinary ExcretionN/A
  • CleranceN/A
  • ToxicitySide effects include: extrapyramidal symptoms, drowsiness, weight gain, dry mouth, constipation, endocrine effects (such as gynaecomastia and menstrual disturbance), sensitivity to sunlight and haemolytic anaemia.
  • LD50 (rat)N/A
  • LD50 (mouse)N/A